BioNTech : Expansion of Pfizer manufacturing capacity in Belgium approved by EMA body

The Committee for Human Medicines, part of the European Medicines Agency (EMA), has recommended the approval of additional manufacturing and filling lines at Pfizer’s manufacturing site in Puurs, Belgium.

According to the EMA, the move would result in a “significant and immediate impact on the supply” of the Covid-19 vaccine developed by BioNTech and Pfizer.

The committee reviewed data submitted by BioNTech, finding that the Puurs facility can consistently produce high-quality vaccines and is capable of increasing production volumes.